BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Cantor Fitzgerald
Queensland Health
Moodys
Cipla
Dow
Merck
AstraZeneca
Julphar

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,741,512

« Back to Dashboard

Summary for Patent: 5,741,512
Title: Pharmaceutical compositions comprising cyclosporins
Abstract:Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.
Inventor(s): Hauer; Birgit (Lahr, DE), Meinzer; Armin (Freiburg/Munzingen, DE), Posanski; Ulrich (Freiburg, DE), Richter; Friedrich (Schonbuhl-Urtenen, CH)
Assignee: Novartis Corporation (Summit, NJ)
Application Number:08/430,770
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 5,741,512

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,741,512

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8821754Sep 16, 1988
United Kingdom8902900Feb 09, 1989
United Kingdom8902903Feb 09, 1989

International Patents Family Members for US Patent 5,741,512

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 403435 ➤ Subscribe
Austria A214289 ➤ Subscribe
Australia 4140089 ➤ Subscribe
Australia 627220 ➤ Subscribe
Belgium 1003105 ➤ Subscribe
Bulgaria 60525 ➤ Subscribe
Canada 1332150 ➤ Subscribe
Switzerland 679118 ➤ Subscribe
Cyprus 1711 ➤ Subscribe
Germany 3930928 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Chinese Patent Office
Baxter
Merck
Healthtrust
Queensland Health
Teva
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot